Cantargia AB (publ)
SSE:CANTA.ST
3.32 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Cantargia AB (publ) |
Symbool | CANTA.ST |
Munteenheid | SEK |
Prijs | 3.32 |
Beurswaarde | 554,400,160 |
Dividendpercentage | 0% |
52-weken bereik | 3.202 - 8.195 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Goran Forsberg |
Website | https://www.cantargia.com |
An error occurred while fetching data.
Over Cantargia AB (publ)
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)